sh-Oligopeptide-4 for Hair Regrowth - Quick Reference Sheet

sh-Oligopeptide-4 for Hair Regrowth

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 Audit

Laboratory-made thymosin beta-4 listed in hair serums. Animals grew hair faster; no trial counted hairs for it alone. Only human scalp study of it alone improved flaking, not hair counts. Clinic blends report thicker-looking hair. Human hair grown outside the body grew slightly less. Vessel growth is a longer-range concern. Whether the product matches the label is an evidence problem. (Full Review)

Protocol

Cosmetic leave-on (Caregen-style serums)
No independent concentration standard
Typically after washing; isolated human gel used 0.5 mg/ml recombinant peptide for 4 weeks
Intradermal cocktail (QR678 Neo)
About eight sessions
Clinic mesotherapy of a six-peptide blend; not an isolated-peptide regimen
Pharmaceutical and gray-market injectables
0.05–25 μg/kg intravenous
Half-life 0.5–2.1 hours; TB-500 fragment protocols are not this molecule
Time to effect
Improved Scalp Flaking and Barrier in Seborrheic Dermatitis
4 weeks
Isolated-peptide gel; not counted hairs
Hair Density When Folded into an Intradermal Growth-Factor Cocktail
3–6 months
Human hair-cycle logic for a countable density change
Isolated Follicle Stem-Cell Activation ⚠️ Conflicted
7 days
Rodent follicle doubling; living human follicles grew less shaft

Benefits

Contraindications
  • World Anti-Doping Agency–tested athletes using injectable thymosin beta-4 or TB-500 (prohibited peptide-hormone class)
  • People with untreated solid tumors or metastases when delivery is systemic, microneedled, or mesotherapy
Key Interactions
  • Minoxidil (oral or topical)
  • Anti-angiogenic cancer drugs (bevacizumab, sunitinib, lenvatinib)
  • Other growth-factor topicals and platelet-rich plasma
  • Ketoconazole shampoo
  • Immunosuppressants (systemic corticosteroids, methotrexate) on infected or barrier-broken scalps

Risk & Side Effects

  • High:
  • Medium: Rare Anti-Drug Antibodies After Intravenous Dosing
  • Low: Local Reactions After Intradermal Cocktail Injection
  • Speculative: Tumor Angiogenesis and Metastasis Facilitation; Product Identity and Contamination

Monitoring

Marker Target Why
Hair density (phototrichogram) Change from own baseline; non-thinning vertex often about 150–250 hairs/cm² Detects conversion to visible terminal hair
Shaft diameter Increase versus that person's baseline Tracks miniaturization, the androgenetic endpoint
Hair-pull test Negative or clearly improved versus baseline Simple shedding check
Adherent flaking / erythema Return toward that person's pre-flare state Captures seborrheic benefit seen with the 0.5 mg/ml gel
Ferritin Often targeted ≥70–100 ng/mL in longevity-oriented hair work Rules out a common alternative cause of shedding
TSH Typically 0.5–2.5 mIU/L in functional practice Hypothyroidism mimics telogen shedding

Cadence: Baseline, then 4 weeks (isolated-gel window), 12 weeks, then every 3–6 months if use continues

Qualitative Assessment

  • Daily shed in the drain or on the pillow relative to that person's baseline
  • Itch, burn, or new papules (small raised bumps) after application (tolerance)
  • Cosmetic coverage on photographs at a fixed length and lighting
  • For athletes, any anti-doping query about peptide products